These effects may be comparable to changes induced by medical therapy, i.e., GLP-1 receptor agonists such as semaglutide 0.4 mg subcutaneously daily, a promising candidate for NASH therapy [3]: At one year, our data showed a reduction in CAP, AST, ALT, and LSM by − 42 dB/m, and factors of 0.74, 0.63, and 0.83, respectively. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.